Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this case an undisclosed cardiometabolic targetTotal potential deal value up to $186M in upfront, development and commercial milestone payments, in addition to R&D funding and tiered royalty payments on commercial sales WALTHAM, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Photys Therapeutics, Inc., a proximity-based therapeutics company, today announced a multi-year collaborati ...

A box of Ozempic made by Novo Nordisk is seen at a pharmacy in London, Britain March 8, 2024.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.There may be a new, unintended side effect linked to Novo Nordisk's blockbuster diabetes injection, Ozempic. Danish health authorities on Monday said they are asking the European Union's drug regulator to review the findings of two D ...

Novo Nordisk (NVO) announced that it plans to invest DKK 8.5 billion, translating to approximately $1.2 billion, to set up a new production facility in Odense, Denmark. Per NVO, the new site will include a state-of-the-art production facility and warehouse covering more than 40,000 m². Designed with modularity and flexibility in mind, it will support the production of various product types for rare diseases, including haemophilia, both now and in the future.Novo Nordisk reported that construction has alread ...

Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.   The new site will feature a state-of-the-art finished production facility and warehouse spanning over 40,000 m2. Designed to be modular and flexible, it will accommodate multiple product types wit ...

HIGHLIGHTS Novo has strengthened its high-quality, Australian based exploration portfolio by executing binding term sheets relating to TechGen Metals Limited’s (ASX: TG1) (TechGen) John Bull Gold Project in the New England Orogen of NSW, and Manhattan Corporation Limited’s (ASX: MHC) (Manhattan) Tibooburra Gold Project in the Albert Goldfields in northwestern NSW.Both projects demonstrate prospectivity for significant discovery and resource definition and align with Novo’s strategy of identifying and explor ...

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label expansion of Ozempic (semaglutide) to treat patients with type II diabetes (T2D) and chronic kidney disease (CKD) in the EU. Subject to approval, the drug will be indicated as an adjunct to the standard of care for the prevention of the progression of renal impairment in T2D and CKD patients. A final decision from EMA is expe ...

公司表现 - 诺和诺德公司（NVO）自10月初以来股价下跌了3.7% [1] 分析师观点 - 分析师对诺和诺德公司持有“持有”评级 [1] 分析师背景 - 分析师Manika拥有超过20年的宏观经济学经验，涉及投资管理、股票经纪和投资银行等行业 [1] - Manika运营的Long Term Tips（LTT）专注于绿色经济中的代际机会 [1] - Green Growth Giants是Manika的投资集团，进一步深入探讨绿色经济领域的机会 [1]

A view of the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Novo Nordisk just got a step closer to significantly improving supply for its blockbuster weight loss drug Wegovy and diabetes treatment Ozempic.The Danish drugmaker's parent company, Novo Holdings, ...

核心观点 - 礼来公司(Eli Lilly and Company)的Zepbound药物在帮助肥胖成年人减重方面比诺和诺德(Novo Nordisk)的Wegovy更有效，导致公司股价上涨 但技术分析表明，股价可能面临前高点的阻力，上涨可能短暂 [1][3] 药物效果 - Zepbound在3b期试验中显示出20.2%的减重效果，显著优于Wegovy的13.7%减重效果 [1] 股价走势 - 礼来公司股价在7月达到约$956.90的高点后回落，8月底再次接近该水平时遇到阻力并反转 [1] - 9月底股价达到约$937.40的高点，10月中旬再次接近该水平时遇到阻力并再次回落 [1] - 11月初股价达到约$846.50的高点，目前股价再次接近该水平，可能再次遇到阻力并反转 [3] 市场心理 - 股价在之前的高点处通常会遇到阻力，原因是投资者的"买家悔恨"心理 许多在高点买入的投资者后悔自己的决定，希望在股价回升至买入价时卖出以避免损失 [3] - 这种心理导致大量投资者在股价回升至之前的高点时下达卖出订单，从而形成阻力 [3]

核心观点 - Defiance ETFs 推出了首个专注于丹麦制药巨头诺和诺德（Novo Nordisk）的单股杠杆ETF NVOX，为零售投资者提供双倍于诺和诺德股票每日价格变动的长期暴露，无需保证金账户，提供了一种创新的交易选择[1] 公司动态 - Defiance ETFs 强调了 NVOX 的战略重要性，指出诺和诺德在蓬勃发展的减肥市场中的核心地位，公司生产的 Ozempic 和 Wegovy 药物使其成为该行业的重要参与者[2] - 诺和诺德在2024年第三季度报告了 Wegovy 销售额达到173亿丹麦克朗，增长81%，Ozempic 销售额在固定汇率下增长26%，达到298亿丹麦克朗[3] 行业趋势 - 减肥市场被描述为一个多万亿的机会，投资者可以利用 NVOX 来抓住这一机会[4] - 抗肥胖药物的使用，包括胰高血糖素样肽-1受体激动剂，与酒精使用障碍的低发生率和复发率相关[5] 市场表现 - 诺和诺德股票在周二盘前交易中上涨2.02%，达到$110.86[6]